This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ryan, C. J. Articles by Small, E. J. Search for Related Content PubMed PubMed Citation Articles by Ryan, C. J. Articles by Small, E. J.

Early Versus Delayed Androgen Deprivation for Prostate Cancer: New Fuel for an Old Debate

Charles J. Ryan, Eric J. Small

From the Department of Medicine and the Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

Address reprint requests to Charles J. Ryan, MD, Urologic Oncology Program, UCSF Comprehensive Cancer Center, 1600 Divisadero St, San Francisco CA 94143; e-mail: ryanc{at}medicine.ucsf.edu.

The purpose of this review is to discuss the recent increase in data supporting the use of androgen ablation early in the clinical course for patients with nonmetastatic prostate cancer. We systematically reviewed recent publications that report on the use of androgen deprivation (AD) in nonmetastatic prostate cancer patients from the 2003 and 2004 procedings of the American Society of Clinical Oncology, the 2003 and 2004 procedings of the American Urological Association as well as published literature from 2003 to 2005. Five recently published mature randomized trials of AD plus local therapy were evaluated plus two large data sets on the use of AD for patients with serologic relapse after local therapy. Four mature randomized studies demonstrate an overall survival benefit to the use of AD in conjunction with definitive local therapy (three with radiation and one with surgery). One retrospective analysis suggests that AD administered early after serologic progression improves overall survival, and one retrospective analysis shows a reduction in metastasis-free survival but has not yet shown an overall survival benefit. For patients with nonmetastatic prostate cancer with high-risk features, as well as those for serologic relapse, the use of AD before the development of metastatic disease is supported by long-term outcomes from a series of clinical trials. Consideration of AD is therefore warranted early in the clinical course of high-risk patients.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				V. B. Shahinian, Y.-f. Kuo, J. L. Freeman, E. Orihuela, and J. S. Goodwin Characteristics of Urologists Predict the Use of Androgen Deprivation Therapy for Prostate Cancer J. Clin. Oncol., December 1, 2007; 25(34): 5359 - 5365. [Abstract] [Full Text] [PDF]

				F. Shimizu, A. Igarashi, T. Fukuda, Y. Kawachi, S. Minowada, Y. Ohashi, and M. Fujime Decision Analyses in Consideration of Treatment Strategies for Patients with Biochemical Failure After Curative Therapy on Clinically Localized Prostate Cancer in the Prostate-Specific Antigen Era Jpn. J. Clin. Oncol., October 22, 2007; (2007) hym105v1. [Abstract] [Full Text] [PDF]

				G. M. Duchesne, R. Syme, and D. Howell How Early Is Early: Androgen Deprivation for Prostate-Specific Antigen Relapse in Prostate Cancer J. Clin. Oncol., June 20, 2006; 24(18): 2964 - 2964. [Full Text] [PDF]

				C. J. Ryan In Reply J. Clin. Oncol., June 20, 2006; 24(18): 2965 - 2965. [Full Text] [PDF]

				E. J. Small and E. A. Klein Challenges and Future Directions in the Prevention and Management of Prostate Cancer J. Clin. Oncol., November 10, 2005; 23(32): 8143 - 8145. [Full Text] [PDF]